OMIC Singular Genomics Forward P/S Multiple
Sequencing system sales depend on research institute grants and biomolecule analysis precision, which impacts the forward P/S multiple, where the current level is 18.80. Singular Genomics Systems (OMIC) revenues are based on the supply of equipment and consumables for oncology. Current workforce optimization and a focus on clinical trials are stabilizing quotes, helping investors recognize asset overheating in a timely manner and assess its margin of safety.
Summary analytical data breakdowns for Singular Genomics Corp (OMIC)
- current price and projected stock value:
- market capitalization data:
- issuer book value statistics:
- debt and liquidity data:
Debt to Equity Singular Genomics Systems|OMIC - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Singular Genomics Systems|OMIC - Company Total Debt Obligations|Debts to Book Capitalization Singular Genomics Corp|OMIC - Company Long-Term Liabilities|Company Short-Term Debt Singular Genomics|Quick Liquidity Indicator singulargenomics.com
- business earnings and investment ratios data:
OMIC - Final Profit|Expected Profit Singular Genomics Systems|OMIC - Business Payback Period|Projected Price to Earnings Singular Genomics Systems Inc|OMIC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Singular Genomics Corp|OMIC - Operating income before deduction of amortization|Net earnings per share for the last 12 months Singular Genomics|OMIC - Earnings per share for the last four quarters|Quarterly EPS earnings growth singulargenomics.com|OMIC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Singular Genomics Systems
- sales and revenue indicators:
Comprehensive company analysis:Singular Genomics OMIC
Stable component supplies for Singular Genomics Systems (OMIC) strengthen its operational base, which is reflected in the organization's forward P/S ratio. This indicator compares current market capitalization with expected revenue, transforming static quarterly forecasts into a dynamic valuation curve that allows investors to promptly recognize asset overheating and determine the business's fundamental value relative to its future earnings.
Competitors of Singular Genomics Systems (OMIC)
Forward P/S Multiple TEM (Tempus AI, Inc.)|Projected Price to Revenue Qiagen NV|Ionis Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Repligen Inc.|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CRSP|Price-to-Projected Revenue Ratio GeneDx|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Forward Price-to-Revenue Multiple Sarepta Corp SRPT|Forward P/S Multiple TWST (Twist Bioscience)|Market Cap to Expected Sales Ratio 10xgenomics.com (TXG)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Stoke Therapeutics Inc (STOK) - Forward Price-to-Revenue Multiple|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|SION: Forward Price to Sales|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|uniQure Corp - Forward Price-to-Revenue Multiple|MeiraGTx Corp (MGTX) - Market Cap to Future Revenue Ratio|RGNX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio solidbio.com SLDB|OCGN (Ocugen) - Forward Price-to-Revenue Multiple|PACB: Price to Expected Revenue Ratio|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Design Corp DSGN|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|Forward Price-to-Revenue Multiple 4dmoleculartherapeutics.com FDMT|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Market Cap to Expected Sales Ratio Korro Bio Inc. (KRRO)|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Silence Therapeutics Corp|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Codexis|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Nautilus Biotechnology Inc (NAUT) - Market Cap to Expected Sales Ratio|Forward P/S Multiple MGX|Forward Price-to-Revenue Multiple Precision BioSciences Inc. DTIL|Forward P/S Multiple GBIO (Generation Bio)|BOLD: Market Cap to Projected Revenue|XCUR - Price-to-Projected Revenue Ratio|IMNN (Imunon, Inc.) - Market Cap to Projected Revenue|PHIO: Forward P/S Multiple|Mustang Bio (MBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TransCode Therapeutics Inc.|Bionano (BNGO) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APDN|Market Cap to Expected Sales Ratio bluebird bio Inc.|Price-to-Projected Revenue Ratio ImmunoPrecise Antibodies Ltd. IPA|OMGA: Market Cap to Projected Revenue|Regulus Therapeutics - Forward P/S Multiple|Projected Price to Revenue syros.com (SYRS)|TBIO (Telesis Bio) - Forward Price-to-Revenue Multiple|TRACON Pharmaceuticals Inc. (TCON) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Unity Bio
